AKT1 and pulmonary fibrosis: Its antifibrotic effects are particularly notable, as it inhibits NLRP3-associated inflammation and suppresses the PI3K/AKT/mTOR pathway, thereby reducing fibrotic processes in amiodarone-induced pulmonary fibrosis [192].